FDA Issues Guidance for Psychedelics Clinical Trials

July 8, 2023 · Cannabis Now

The US Food and Drug Administration (FDA) has issued new draft guidance that highlights key considerations for researchers conducting clinical trials of psychedelic drugs for the treatment of medical conditions. The move, which was announced by the agency on June 23, marks the first time the FDA has issued guidance for investigating psychedelics, including psilocybin, LSD and MDMA, which have shown potential as possible treatments for serious mental health conditions. The guidance “describes basic considerations throughout the drug development process including trial conduct, data collection, subject safety and new drug application requirements,” the agency said.

“Psychedelic drugs show initial promise as potential treatments for mood, anxiety and substance use disorders,” Tiffany Farchione, M.D., director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research, said in a statement from the agency. “However, these are still investigational products. Sponsors evaluating the therapeutic potential of these drugs should consider their unique characteristics when designing clinical studies.”

Psychedelics For Mental Health

Growing interest in the therapeutic potential of psychedelics has led to research evaluating the drugs as possible treatments for medical conditions, including depression, anxiety, substance misuse disorders and post-traumatic stress disorder (PTSD). Early studies have been promising, and the FDA has granted psilocybin and MDMA status as “breakthrough therapies,” a designation indicating that clinical evidence suggests a therapy shows a substantial improvement over standard treatments for a particular medical condition.

However, the FDA noted when it released the agency’s new draft guidance that studying psychedelics “presents a number of unique challenges that require careful consideration.” The guidelines were developed to advise researchers on study design and other considerations as they develop medications that contain psychedelics, including “classic psychedelics” such as psilocybin and lysergic acid diethylamide (LSD), which are typically understood to be drugs that act on the brain’s serotonin system, as well as “entactogens” or “empathogens” such as methylenedioxymethamphetamine (MDMA).

The FDA noted that many psychedelic drugs produce psychoactive effects that may make them more susceptible to misuse. The guidance also notes that research into Schedule 1 drugs such as psilocybin is subject to tighter controls and must comply with requirements set by the Drug Enforcement Administration (DEA).

“The evidentiary standard for establishing the effectiveness of psychedelic drugs is the same as for all other drugs,” the FDA said. “However, there are unique factors investigators may need to consider when designing their clinical trials if those trials are to be considered adequate and well-controlled. The draft guidance also addresses the role of psychotherapy in psychedelic drug development, considerations for safety monitoring and the importance of characterizing dose-response and the durability of any treatment effect.”

Lawmakers Applaud

Only days before the FDA issued its draft guidance for researching psychedelic drugs, a bipartisan trio of lawmakers in the US House of Representatives introduced legislation to direct the agency to take such action. The bill, H.R.4242, was filed on June 21 by Rep. Dan Crenshaw (R-TX) and Rep. Mariannette Miller-Meeks (R-IO), as well as California Democratic Rep. Ro Khanna. If passed, the legislation would direct the Secretary of Health and Human Services, working through the FDA, to release guidelines for research into medical conditions, including PTSD and traumatic brain injury. After the guidelines were released, the lawmakers behind the bill praised the FDA for taking the step.

“Many Veterans find guided use of psychedelics with assisted therapy as a way to successfully treat the excruciating, post-traumatic pain they face, with better outcomes and less medication side effects,” Miller-Meeks, a medical doctor, said in a statement on June 30. “As a physician, I know the importance of medical research and I am encouraged by the FDA’s support and guidance regarding psychedelic clinical trials. This important step gives our Veterans another option and hope when they feel they’ve run out of methods to cope.”

“I’m glad the FDA is taking this first step of issuing guidance for psychedelic clinical trials—and listening to my bipartisan legislation with Reps. Miller-Meeks and Khanna,” Crenshaw added. “It’s critical we get this right for the researchers doing this important scientific work. We need this guidance to expand clinical trial access so that we can push towards life-saving psychedelic therapies for our veterans, service members, and people living with PTSD, traumatic brain injury, and substance abuse disorder.”

The FDA published a notice about the new draft guidance for psychedelic research in the Federal Register on June 26. The proposal is now in the midst of a 60-day public comment period for interested parties to provide input on the draft and submit suggestions for the agency to consider before adopting a final version of the guidelines.

“By publishing this draft guidance, the FDA hopes to outline the challenges inherent in designing psychedelic drug development programs and provide information on how to address these challenges,” Farchione said. “The goal is to help researchers design studies that will yield interpretable results that will be capable of supporting future drug applications.” (Full Story)

In categories:Psychedelics Research
Next Post

Australia Becomes the First Country in the World to Legalize Psychedelics for Medical Prescriptions

Last week, Australia made headlines around the world for being the first country ever that legally allowed MDMA and magic mushrooms to be prescribed by licensed psychiatrists for the treatment of mental health conditions. This is surprisingly good news albeit controversial, considering…
Previous Post

Bipartisan Lawmakers Applaud FDA For Publishing Psychedelics Research Guidance, As They Requested In New Congressional Bill

Bipartisan congressional lawmakers are applauding the Food and Drug Administration (FDA) for releasing first-ever draft guidance on psychedelics research—a development that they had requested through a new bill just days before the agency took the step. Reps. Dan Crenshaw (R-TX), Mariannette…
Random Post

Kentucky gives initial OK to emergency rule for intoxicating hemp products

A key legislative subcommittee in Kentucky approved an emergency rule designed to regulate intoxicating hemp-derived products differently than nonintoxicating products. It’s the third time the regulations have been amended, according to news website Kentucky Today, and the emergency rule will remain in…
Random Post

Ireland’s First Cannabis Clinic Opens Four Years After Medical Program Launches

Medicann is launching the first medical cannabis clinic in Ireland and is immediately accepting patients who believe they may be eligible for treatment, according to a news release. The clinic will cover “all conditions treatable with medicinal cannabis,” not limited to…
Random Post

Ohio Pharmacy Board Would No Longer Regulate Medical Cannabis Dispensaries Under Gov.’s Proposed Budget

Under Gov. Mike DeWine’s executive budget, the Ohio Board of Pharmacy would no longer have responsibilities regulating the state’s medical cannabis dispensaries, Cleveland.com reports. The governor’s plan would transfer some of the pharmacy board’s responsibilities to the Department of Commerce, but the…
Random Post

Green Market Report Women’s Leadership Awards: Rebecca Rutenberg

Rebecca got involved in cannabis in 2014. Legal: Rebecca Rutenberg, Vicente With more than 50 cannabis clients, legal wizard Rebecca Rutenberg is plenty busy for the foreseeable future, helping them win licenses all over the U.S. East Coast, from Florida…